Speech, Linguistic and Acoustic Markers in Parkinson's Disease

NCT04273672 | Completed Results

• 2 other identifiers: H000115235K23DC016656
• Study Type: observational
• Target: 58
• Locations: 1 country
• Sites: 1

Brief Summary

The Investigators aim to identify speech and language markers that provide information on cognitive function and predict cognitive decline in Parkinson's disease. The Investigators will administer speech tasks and cognitive assessments to participants with Parkinson's disease and healthy controls. The Investigators will also explore the associations between genetic factors and speech and cognitive status in Parkinson's disease.

Conditions

Parkinson Disease; Cognitive Impairment, Mild; Speech

Outcome Measures

Primary Outcomes (2)

• Mild Cognitive Impairment

  Mild cognitive impairment classified by Movement Disorders Society Task Force Level II Critieria

  baseline

• Mean Fundamental Frequency

  These acoustic measures during spontaneous speech (picture description) were calculated using Praat

  baseline

Study Arms (2)

Parkinson's Disease

Subjects with Parkinson's Disease

Diagnostic Test: Cognitive Battery; Behavioral: Voice, Speech and Language Analysis; Behavioral: Questionnaires and Clinical Assessments; Genetic: DNA Analysis

Control

Subjects without Parkinson's Disease

Diagnostic Test: Cognitive Battery; Behavioral: Voice, Speech and Language Analysis; Behavioral: Questionnaires and Clinical Assessments

Interventions

Cognitive Battery DIAGNOSTIC_TEST

Participants will be asked to complete a series of cognitive testing (testing of concentration, memory, and other thinking abilities).

Control; Parkinson's Disease

Voice, Speech and Language Analysis BEHAVIORAL

Participants will be asked to perform speaking and reading tasks, which will be recorded. Participants will be asked to complete a laptop-based test of language comprehension.

Control; Parkinson's Disease

Questionnaires and Clinical Assessments BEHAVIORAL

Participants with Parkinson's disease will complete an examination of their symptoms and questionnaires assessing disease symptoms, mood and activities of daily living. Healthy controls participants will be asked to complete questionnaires on mood.

Control; Parkinson's Disease

DNA Analysis GENETIC

Participants will have their blood drawn for DNA analysis.

Parkinson's Disease

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults with Parkinson's Disease and mild cognitive impairment or normal cognition as well as controls

You may qualify if:

• Parkinson's Disease (or healthy control)
• Disease duration ≥ 2 years
• Mild cognitive impairment or normal cognition

You may not qualify if:

• Diagnosis of dementia (MoCA \<21)
• Adults unable to consent
• Age \< 18
• Pregnant women
• Prisoners
• Non-English speakers
• Any neurological disorder other than PD
• Deep brain stimulator placement
• Severe, unstable psychiatric disorder
• Unintelligible speech due to effects of PD
• Visual acuity or color vision impairment that would interfere with cognitive testing
• Other voice, speech or swallowing disorders or history of surgery involving palate/nasopharynx/larynx/vocal cords

Sponsors & Collaborators

• University of Massachusetts, Worcester: lead
• Boston University: collaborator
• VA Puget Sound Health Care System: collaborator
• National Institute on Deafness and Other Communication Disorders (NIDCD): collaborator
• Massachusetts Institute of Technology/Lincoln Labs: collaborator

Study Sites (1)

UMass Medical School/UMass Memorial Medical Center

Worcester, Massachusetts, 01655, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood samples

MeSH Terms

Conditions

Parkinson Disease; Cognitive Dysfunction; Speech

Interventions

Voice; Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Cognition Disorders; Neurocognitive Disorders; Mental Disorders; Verbal Behavior; Communication; Behavior

Intervention Hierarchy (Ancestors)

Respiratory Physiological Phenomena; Circulatory and Respiratory Physiological Phenomena; Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Results Point of Contact

• Title: Kara Smith, MD
• Organization: University of Massachusetts Medical School

kara.smith@umassmed.edu

5083342527

Study Officials

• Kara Smith, MD

  UMass Medical School

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor of Neurology

Study Record Dates

• First Submitted: February 12, 2020
• First Posted: February 18, 2020
• Study Start: January 13, 2020
• Primary Completion: September 1, 2023
• Study Completion: February 28, 2025
• Last Updated: June 10, 2025
• Results First Posted: June 10, 2025

Record last verified: 2025-06

Locations

US (1)